Catalog No.
DHA42303
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-nd
Clonality
Monoclonal
Target
ANG-2, ANGPT2, Angiopoietin-2
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
O15123
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
REGN-910, CAS: 1296818-77-3
Clone ID
Nesvacumab
Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease, PMID: 31513439
Innovative therapies for neovascular age-related macular degeneration, PMID: 31298960
Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration, PMID: 28756707
A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors, PMID: 26490310
Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer, PMID: 27841282
Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial., PMID:37008402
Longitudinal Quantitative Ultrawide-field Fluorescein Angiography Dynamics in the RUBY Diabetic Macular Edema Study., PMID:36736895
INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial., PMID:35234673
The emerging role of the Angiopoietin-Tie pathway as therapeutic target for treating retinal diseases., PMID:35098845
Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease., PMID:31513439
Innovative therapies for neovascular age-related macular degeneration., PMID:31298960
Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration., PMID:28756707
Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer., PMID:27841282
A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors., PMID:26490310
For research use only. Not for human or drug use.
